Stanozolol Hilma Biocare USA
$79.00
Product Short Description
Stanozolol 10 mg 100 Tabs Hilma Biocare USA delivers stanozolol (C21H32N2O), the 17α-methyl-5α-dihydrotestosterone pyrazole derivative exhibiting lean anabolic response (~320:30 ratio) with zero aromatization, at exact 10 mg strength replicating historical Winstrol formulation. Domestic U.S. production eliminates customs exposure serving DEA Schedule III compliant institutional channels through verified performance networks.
Product Overview
Hilma Biocare USA’s Stanozolol 10 mg presents stanozolol, featuring unique pyrazoline ring substitution conferring exceptional oral bioavailability (~9 hour half-life) and SHBG displacement alongside dry anabolic effects, in small round white scored tablets matching Winstrol (Winthrop) morphology for institutional catalog integration across DEA-registered platforms. The 100-tablet HDPE bottle configuration supports CIII-compliant inventory reconciliation under 21 CFR 1304.22 requiring detailed Schedule III tracking for institutional handlers maintaining federal compliance.
U.S.-domiciled GMP manufacturing maintains molecular specifications (MW 328.49) distinguishing legitimate Schedule III pedigree from underground powder conversions exhibiting characteristic under-dosing documented across analytics. This authentic presentation serves institutional buyers requiring Form 222 triplicate documentation across U.S. jurisdictions, eliminating international sourcing risks.
Hilma Stanozolol positions exclusively within verified DEA Schedule III ecosystems targeting licensed institutional clientele under 21 CFR 1301.13.
Brand & Manufacturer Information
Hilma Biocare USA manufactures DEA Schedule III controlled substances through domestic GMP facilities serving institutional performance networks requiring DEA registrant verification. Stanozolol 10 mg anchors Hilma’s non-aromatizing oral catalog alongside Anavar/Primo maintaining dosage standardization while authenticating supply chain legitimacy versus powder-pressed alternatives rejected by institutional handlers.
Domestic warehousing supports Form 222 platforms eliminating customs risk while serialized batch documentation verifies 10 mg potency distinguishing Hilma from non-pharmaceutical origins.
Active Compound Information
Contains stanozolol (17α-methyl-5α-androstan-17β-ol-[3,2-c]pyrazole), DHT-derived anabolic steroid exhibiting pyrazoline ring fusion conferring 3x testosterone anabolic potency with minimal androgenic activity characteristic of 17α-alkylated non-aromatizing steroids. DEA Schedule III classification reflects joint/lipid stress potential and moderate hepatotoxicity requiring lipid monitoring.
10 mg strength matches historical Winstrol 10 mg reference while 100-tablet count supports institutional packaging. Molecular formula C21H32N2O; WADA S1.1a prohibited globally.
Product Specifications
| Specification | Details |
|---|---|
| Product Name | Stanozolol 10 mg 100 Tabs Hilma Biocare USA |
| Active Compound | Stanozolol (C21H32N2O) |
| Strength | 10 mg per round scored tablet |
| Quantity | 100 tablets per HDPE bottle |
| Form | Oral scored tablets (Winstrol equivalent) |
| Category | DEA Schedule III controlled substance |
| Appearance | White, round, single-scored |
| Molecular Weight | 328.49 g/mol |
| Half-Life | ~9 hours |
| Label Elements | “10 mg”, CIII warnings, serialized lot |
Quality Control & Testing Standards
10 mg stanozolol mandates USP <621> potency assay (HPLC 95-105%), USP <711> dissolution, USP <905> uniformity, and pyrazoline verification confirming pharmaceutical-grade specifications. Hilma batch records document C21H32N2O identity distinguishing GMP production from underground conversions.
100-tablet CIII configuration incorporates USP <671> HDPE barriers with child-resistant closure satisfying 21 CFR 310.310(a). Stability maintains ICH Q1A(R2) 36-month shelf-life.
Intended Use & Market Positioning
Stanozolol 10 mg serves DEA-registered CIII institutional researchers managing non-aromatizing Schedule III anabolic inventories through encrypted fulfillment requiring Form 222 accountability.
Zero protocols, cycles, or outcomes represented maintaining commercial CIII positioning.
Legal & Regulatory Disclaimer
Stanozolol constitutes DEA Schedule III under 21 USC §812; non-medical handling violates Controlled Substances Act (5 years/$250,000 penalties). Institutional buyers assume Form 222/DEA licensing liability; no medical claims provided.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
Reviews
There are no reviews yet.